Mengyuan Fang, None;
wenying fan, None;
Yue Shi, None;
Michael Ip, Allergan (C), Astellas Institute for Regenerative Medicine (C), Boehringer Ingelheim (C), Genentech (C), Omeros (C), Quark (C), Thrombogenics (C);
Charles Wykoff, Adverum Biotechnologies (F), Aerpio Therapeutics (F), Alcon Laboratories (C), Alcon Laboratories (F), Alimera Sciences (C), Allergan (C), Allergan (F), Apellis Pharmaceutical (C), Apellis Pharmaceutical (F), Bayer AG (C), Clearside Biomedical (C), Clearside Biomedical (F), D.O.R.C. International (C), Genentech (C), Genentech (F), Novartis International AG (C), Novartis International AG (F), ONL Therapeutics (C), Ophthotech Corporation (F), Regeneron Pharmaceuticals (C), Regeneron Pharmaceuticals (F), Regenxbio (C), Regenxbio (F), Roche (C), Santen (C);
Kang Wang, None;
Khalil Falavarjani, None;
David Brown, Aerpio (C), Alcon/Novartis (C), Allegra (C), Allergan, Clearside Biomedical (C), Genentech (F), Genentech/Roche (C), Heidelberg Engineering (C), Optos/ Nikon (C), Regeneron/Bayer (C);
Jano Hemert, None;
Srinivas Sadda, Allergan (C), Amgen (C), Carl Zeiss Meditec (F), Centervue (C), Centervue (F), Genentech/Roche (C), Heidelberg (C), Nidek (F), Novartis (C), Optos (C), Optos (F), Oxurion (C), Topcon (F)